<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[gilead Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/gilead.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to gilead]]></description>
	<s:counts start="0" returned="20" found="593" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Gilead: Little To Show After Cardiovascular Push]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F178280-gilead-little-to-show-after-cardiovascular-push%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Hopes were not particularly high for Gilead Science&#8217;s GILD hard-to-treat hypertension treatment, darusentan, but news that the phase III drug is heading for the R&D dustbin is certainly disappointing. Consensus for sales in 2014 had already come down by almost a third to $164 million since dubious...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 15 Dec 2009 10:15:30 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Closer to FDA Approval for CF Drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F177888-gilead-closer-to-fda-approval-for-cf-drug%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Gilead Sciences, Inc GILD received a positive opinion from the Anti-Infective Drugs Advisory Committee of the US Food and Drug Administration FDA. Gilead is seeking FDA approval for inhalable aztreonam for the treatment of lung infection caused by Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Sat, 12 Dec 2009 11:16:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Patent Pools, Expensive Drugs and AIDS In Africa]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/patent-pools-expensive-drugs-aids/23461/]]></link>
		<description><![CDATA[At a Doctors Without Borders clinic in Khayelitsha, South Africa, patients are now resistant to the first-line regimen of HIV drugs, a generic combo based on the old drug D4T, which is barely used in the US or Europe because they have serious side effects and must be taken multiple...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Fri, 11 Dec 2009 06:45:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/forbes.html"><![CDATA[Forbes]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[Patent]]></category>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Seeks to Commercialize Viread in China for Hepatitis B]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175261-glaxosmithkline-seeks-to-commercialize-viread-in-china-for-hepatitis-b%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[ChinaBio Today submits:  GlaxoSmithKline GSK and Gilead Sciences GILD agreed on an Asian marketing plan for their jointly owned treatment for hepatitis B, Viread® tenofovir disoproxil fumarate. GSK will have exclusive rights to commercialize the drug for hepatitis B in China. Gilead will own exclusive rights Hong Kong, Singapore,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 25 Nov 2009 04:11:15 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/china.html"><![CDATA[China]]></category>
		<category domain="http://resources.bnet.com/topic/chinabio+today.html"><![CDATA[ChinaBio Today]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GILD,GSK</category>
	</item>
	<item>
		<title><![CDATA[H&Q Healthcare Investors Closed-End Fund Decently Valued]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F173529-h-q-healthcare-investors-closed-end-fund-decently-valued%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[George Spritzer submits:  H&Q Healthcare Investors HQH appears to a be a decent value now within the closed-end fund universe. It is broadly diversified, and primarily invests in biotechnology, medical devices, pharmaceuticals and medical delivery. It also invests a limited portion of the portfolio in smaller, emerging companies and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Mon, 16 Nov 2009 05:39:06 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/etf.html"><![CDATA[ETF]]></category>
		<category domain="http://resources.bnet.com/topic/george+spritzer.html"><![CDATA[George Spritzer]]></category>
	</item>
	<item>
		<title><![CDATA[ViiV chief vows joint venture will help battle HIV]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/viiv-vows-joint-venture-battle/18873/]]></link>
		<description><![CDATA[The new head of the pioneering HIV joint venture between GlaxoSmithKline and Pfizer predicts his company can operate for at least five years without fresh funding from its shareholders. Dominique Limet, chief executive of ViiV Healthcare, which was formally launched yesterday, says it will generate Â£1.6bn a year in sales...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 04 Nov 2009 03:17:48 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/hiv+virus.html"><![CDATA[HIV Virus]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/intel+viiv.html"><![CDATA[Intel Viiv]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences Is in Great Health]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F167928-gilead-sciences-is-in-great-health%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  &#8220;Check out Gilead. Profit up 36% from a year ago. Well ahead of expectations at 78 cents [non-GAAP] versus a 67 estimate. The revenues grew 31% from a year ago. Product sales strong, royalties strong, but the stock is down. Only thing I can see, that...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 12:00:16 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Stock Futures Dip; Raft of Earnings Eyed]]></title>
		<link><![CDATA[http://industry.bnet.com/financial-services/news-analysis/stock-futures-dip-raft-earnings/16748/]]></link>
		<description><![CDATA[(<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>) - U.S. stock index futures pointed to a lower open on Wall Street on Wednesday, with futures for the S&P 500 down 0.24 percent, Dow Jones futures down 0.1 percent and Nasdaq 100 futures down 0.34 percent. Yahoo Inc YHOO will be in focus after the company beat Wall...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 03:17:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/wall+street.html"><![CDATA[Wall Street]]></category>
		<category domain="http://resources.bnet.com/topic/stock.html"><![CDATA[Stock]]></category>
		<category domain="http://resources.bnet.com/topic/yahoo%2521+inc..html"><![CDATA[Yahoo! Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/fdic.html"><![CDATA[FDIC]]></category>
		<category domain="http://resources.bnet.com/topic/dow+jones+%2526+company+inc..html"><![CDATA[Dow Jones & Company Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DJ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">YHOO</category>
		<category domain="tickers">DJ,YHOO</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences, Inc. Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-354660.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions And our first question comes from the line of Geoff Meacham with JPMorgan. Go ahead. Geoff Meacham &#8211; JPMorgan Hey guys, congrats on the quarter and thanks for taking the question. Question for you, I am trying to reconcile product sales guidance with...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 20 Oct 2009 20:32:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/guidance.html"><![CDATA[Guidance]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Taking Profits from Swine Flu with Tamiflu]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F160871-taking-profits-from-swine-flu-with-tamiflu%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  Flu season is approaching quickly and fresh fears over a possible H1N1 epidemic have taken hold.  Hospitals and pharmacies are stocking up on medications to counter such an outbreak, and the most popular drug to treat flu is Tamiflu.  Tamiflu was developed by Gilead...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 10 Sep 2009 09:33:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences: Expect Share Price to Move Up]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F159973-gilead-sciences-expect-share-price-to-move-up%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Gilead Sciences GILD is a good bio-technology companies with their strong franchise in HIV, a growing franchise in Hepatitis and potential in cardio-vascular therapies. Many think of Gilead as the provider of Tamiflu, a therapy for influenza. However, Tamiflu is a small part of the story and it has limited...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 04 Sep 2009 02:43:43 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/hans+wagner.html"><![CDATA[Hans Wagner]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Lawyer Says Drugmaker Celgene Stole Her Idea]]></title>
		<link><![CDATA[http://industry.bnet.com/healthcare/news-analysis/lawyer-drugmaker-celgene-stole-idea/9281/]]></link>
		<description><![CDATA[In 1996, Beth Jacobson was watching her husband, a 35-year-old cardiologist, die from the blood cancer multiple myeloma. She spent her nights reading medical journals at his bedside and her days calling doctors. One Saturday night, Judah Folkman, the famed Harvard cancer researcher, returned her call, and they came up...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 26 Aug 2009 07:55:12 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/idea.html"><![CDATA[idea]]></category>
		<category domain="http://resources.bnet.com/topic/celgene+corp..html"><![CDATA[Celgene Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CELG</category>
		<category domain="tickers">CELG</category>
	</item>
	<item>
		<title><![CDATA[Big Pharma, Polar Bears, and the Need to Specialize]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/pharma-polar-bears-specialize/8263/]]></link>
		<description><![CDATA[For at least a decade, biotechs have been perceived by many observers as the likely evolutionary winners in the race for survival and prosperity in the drug industry. The credit crunch has drastically altered the environment in which companies operate and the biotech business model now looks much less likely...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Wed, 19 Aug 2009 07:20:24 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+company.html"><![CDATA[Pharmaceutical Company]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[biotechnology]]></category>
	</item>
	<item>
		<title><![CDATA[Gilead Subpoena Will Have Investors Guessing: What's Wrong With the CVT Acquisition?]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003724/gilead-subpoena-will-have-investors-guessing-whats-wrong-with-the-cvt-acquisition/]]></link>
		<description><![CDATA[Gilead's single-sentence announcement that it has received a subpoena regarding Ranexa from the Office of the Inspector General of HHS could be nothing or anything. One thing is for sure, securities class-action lawyers will be watching this very closely, as the subpoena comes just a few months after Gilead acquired...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 17 Aug 2009 12:35:35 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/subpoena.html"><![CDATA[Subpoena]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[Investor]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+office.html"><![CDATA[Microsoft Office]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/office+suites.html"><![CDATA[Office Suites]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[Software]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Created "Cocktail Bar for Rats" to Test Anti-Booze Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003690/gilead-created-cocktail-bar-for-rats-to-test-anti-booze-drug/]]></link>
		<description><![CDATA[Gilead has done some entertaining tests of an anti-booze drug in rats. The company introduced rats to sugar water cocktails, and gradually increased the booze content within them. They also set up a rat "bar" -- a special cage  -- where the drinks were served. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 14 Aug 2009 12:56:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/rat.html"><![CDATA[Rat]]></category>
		<category domain="http://resources.bnet.com/topic/cocktail.html"><![CDATA[Cocktail]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/food+%2526+beverage.html"><![CDATA[Food & Beverage]]></category>
		<category domain="http://resources.bnet.com/topic/manufacturing.html"><![CDATA[Manufacturing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Axes 139 Jobs in Colorado; CVT Reps Get Culture Shock]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003663/gilead-axes-139-jobs-in-colorado-cvt-reps-get-culture-shock/]]></link>
		<description><![CDATA[Gilead is laying off 66 people as it closes its Colorado offices to consolidate its operations in California. Gilead "hopes to relocate 73 of the 139 staff" that work in Colorado to California. The move should not be a surprise. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 13 Aug 2009 14:15:04 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/job.html"><![CDATA[Job]]></category>
		<category domain="http://resources.bnet.com/topic/colorado.html"><![CDATA[Colorado]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/recruitment+%2526+selection.html"><![CDATA[Recruitment & Selection]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead to close Colorado offices]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/gilead-colorado-offices/7479/]]></link>
		<description><![CDATA[The biotech has chosen to close the Colorado offices following the $1.4bn (???1bn) acquisition of California-based CV Therapeutics. This created an overlap in expertise that Gilead is resolving by closing the Colorado offices. Gilead hopes to relocate 73 of the 139 staff that work in the Colorado offices. The offices...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 13 Aug 2009 07:01:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/office.html"><![CDATA[office]]></category>
		<category domain="http://resources.bnet.com/topic/colorado.html"><![CDATA[Colorado]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[ETF Spotlight: PowerShares Dynamic Biotech & Genome (PBE)]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152754-etf-spotlight-powershares-dynamic-biotech-genome-pbe%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Tom Lydon ETF Trends submits:  ETF Spotlight on PowerShares Dynamic Biotech & Genome PBE, part of a weekly series. Assets: $148 million Holdings: This fund invests in companies involved in the biotechnology and genome sectors. Some of the top components include ImmunoGen IMGN, Amgen AMGN, Gilead Sciences GILD and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Fri, 31 Jul 2009 12:26:57 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/etf.html"><![CDATA[ETF]]></category>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/tom+lydon.html"><![CDATA[Tom Lydon]]></category>
	</item>
	<item>
		<title><![CDATA[Gilead Q2 Mystery: Purchase of Less-Efficient CVT Made It a More Efficient Company]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003314/gilead-q2-mystery-purchase-of-less-efficient-cvt-made-it-a-more-efficient-company/]]></link>
		<description><![CDATA[Gilead continues to astonish: If you remove the transaction and restructuring costs, the company's acquisition of CV Therapeutics has actually made it even more efficient than it was before. That's unexpected because CVT was an incredibly inefficient producer of its own revenues. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 27 Jul 2009 13:55:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/restructuring.html"><![CDATA[Restructuring]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="tickers">GILD</category>
	</item>
	<item>
		<title><![CDATA[Gilead Sciences, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-323311.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator   Operator Instructions. Our first question comes from the line of Geoff Porges &#8211; Sanford Bernstein. Geoff Porges &#8211; Sanford Bernstein I have a question on a J&J agreement.  Could you clarify the outlook for both parties to develop other combinations?  Can J&J...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 21 Jul 2009 20:05:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/deutsche+bank+ag.html"><![CDATA[Deutsche Bank AG]]></category>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/gilead+sciences+inc..html"><![CDATA[Gilead Sciences Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GILD</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">DB,GILD,JNJ</category>
	</item>
</channel>
</rss>
